DK3110843T3 - Kombinationsterapier med anti-cd38-antistoffer - Google Patents

Kombinationsterapier med anti-cd38-antistoffer Download PDF

Info

Publication number
DK3110843T3
DK3110843T3 DK15755187T DK15755187T DK3110843T3 DK 3110843 T3 DK3110843 T3 DK 3110843T3 DK 15755187 T DK15755187 T DK 15755187T DK 15755187 T DK15755187 T DK 15755187T DK 3110843 T3 DK3110843 T3 DK 3110843T3
Authority
DK
Denmark
Prior art keywords
antibodies
combination therapy
therapy
combination
Prior art date
Application number
DK15755187T
Other languages
English (en)
Inventor
Parul Doshi
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of DK3110843T3 publication Critical patent/DK3110843T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
DK15755187T 2014-02-28 2015-02-25 Kombinationsterapier med anti-cd38-antistoffer DK3110843T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946002P 2014-02-28 2014-02-28
US201462006386P 2014-06-02 2014-06-02
PCT/US2015/017420 WO2015130728A1 (en) 2014-02-28 2015-02-25 Combination therapies with anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
DK3110843T3 true DK3110843T3 (da) 2019-11-11

Family

ID=54006264

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15755187T DK3110843T3 (da) 2014-02-28 2015-02-25 Kombinationsterapier med anti-cd38-antistoffer

Country Status (35)

Country Link
US (4) US9603927B2 (da)
EP (1) EP3110843B1 (da)
JP (1) JP6670248B2 (da)
KR (1) KR20160126026A (da)
CN (1) CN106459184B (da)
AU (1) AU2015223205B2 (da)
BR (1) BR112016019866A2 (da)
CA (1) CA2940864C (da)
CL (1) CL2016002158A1 (da)
CR (1) CR20160388A (da)
CY (1) CY1122398T1 (da)
DK (1) DK3110843T3 (da)
DO (1) DOP2016000224A (da)
EA (1) EA201691747A1 (da)
ES (1) ES2756349T3 (da)
GT (1) GT201600172A (da)
HR (1) HRP20192058T1 (da)
HU (1) HUE046028T2 (da)
IL (1) IL247392B (da)
LT (1) LT3110843T (da)
ME (1) ME03583B (da)
MX (1) MX378546B (da)
MY (1) MY180621A (da)
PE (1) PE20161175A1 (da)
PH (1) PH12016501700A1 (da)
PL (1) PL3110843T3 (da)
PT (1) PT3110843T (da)
RS (1) RS59516B1 (da)
SG (1) SG11201607028XA (da)
SI (1) SI3110843T1 (da)
SM (1) SMT201900637T1 (da)
SV (1) SV2016005267A (da)
UA (1) UA120926C2 (da)
WO (1) WO2015130728A1 (da)
ZA (2) ZA201606682B (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6775422B2 (ja) 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
SG11201704283PA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
JP2017536830A (ja) 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HRP20240338T1 (hr) * 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
MA45255A (fr) 2016-06-14 2019-04-17 Xencor Inc Anticorps inhibiteurs de points de contrôle bispécifiques
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
EP3535295A1 (en) 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
EP3544612A4 (en) * 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
EP3548032A2 (en) * 2016-12-02 2019-10-09 Epizyme, Inc. Combination therapy for treating cancer
IL270066B2 (en) 2017-04-24 2023-10-01 Aurigene Oncology Ltd Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
EP3635001A1 (en) * 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Cd38 modulating antibody
WO2019034752A1 (en) 2017-08-16 2019-02-21 Tusk Therapeutics Ltd Cd38 modulating antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11944644B2 (en) 2017-12-05 2024-04-02 The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof
EP3740198A4 (en) 2018-01-18 2023-08-09 Fred Hutchinson Cancer Center MODIFICATION OF INFLAMMATORY STATES OF IMMUNE CELLS IN VIVO BY MODULATION OF CELL ACTIVATION STATES
KR102861339B1 (ko) 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
KR101997519B1 (ko) * 2018-03-16 2019-07-09 주식회사 지니틱스 디스플레이 패널로부터의 노이즈에 의한 영향 및 공정편차에 따른 에러를 제거하는 터치감지칩
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
BR112021007227A2 (pt) 2018-10-17 2021-08-10 Janssen Biotech, Inc. método para fornecer administração subcutânea de anticorpos anti-cd38
AU2019379858B2 (en) * 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
IL283503B2 (en) * 2018-11-30 2025-10-01 Fond Centro San Raffaele Combination therapy for primary central nervous system lymphoma
JP7418756B2 (ja) 2019-01-23 2024-01-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド 脱免疫化志賀毒素ａサブユニットエフェクターを含むｃｄ３８結合性タンパク質
AU2020211407A1 (en) * 2019-01-23 2021-08-12 Millennium Pharmaceuticals, Inc. Anti-CD38 antibodies
US20220187309A1 (en) * 2019-04-30 2022-06-16 Sarah E. WHEELER Compositions and methods for detection of disease-related antibody
MX2022010549A (es) 2020-02-26 2022-11-16 Biograph 55 Inc Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras.
US20210338766A1 (en) * 2020-04-29 2021-11-04 Onyx Pharmaceuticals, Inc. Methods of treating multiple myeloma
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US20230285365A1 (en) * 2020-08-27 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
CA3216410A1 (en) * 2021-04-21 2022-10-27 Guy Dipierro Methods of treatment and dosing of natural killer cell compositions
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
US20250051473A1 (en) * 2022-02-03 2025-02-13 Igm Biosciences, Inc. Anti-cd38 binding molecules and uses thereof
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
TW202545561A (zh) 2024-01-16 2025-12-01 德商莫菲西斯有限責任公司 抗體的高度濃縮液體製劑

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
WO1992001049A2 (en) 1990-07-13 1992-01-23 The General Hospital Corporation Cd53 cell surface antigen and use thereof
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
WO1998016245A1 (fr) 1996-10-15 1998-04-23 Shionogi & Co., Ltd. Procede de determination d'un auto-anticorps
WO1998016254A1 (en) 1996-10-17 1998-04-23 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
DE69831224T2 (de) 1997-05-02 2006-03-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US6734203B2 (en) 2000-02-15 2004-05-11 Akira Matsuhisa Fused imidazolium derivatives
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
AU6541801A (en) * 2000-06-22 2002-01-02 Idec Pharma Corp Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US6955884B2 (en) 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
NZ536746A (en) 2002-06-13 2007-02-23 Crucell Holland Bv An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
CA2522486C (en) 2003-04-15 2011-02-22 Astellas Pharma Inc. Bromide and crystals thereof
NZ621449A (en) 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1689435A4 (en) 2003-10-22 2007-10-03 Univ Rochester ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS
ES2346978T3 (es) 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
ES2378767T3 (es) 2003-12-23 2012-04-17 Crucell Holland B.V. Molécula de unión humana contra CD1a
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
EP1888647A2 (en) 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
PL2860192T3 (pl) 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
AU2006329944A1 (en) * 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using CD40 binding agents
EP2049109B1 (en) 2006-08-02 2015-11-18 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
AU2007302448C1 (en) * 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
MX2009010179A (es) 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
JP2010529024A (ja) 2007-06-01 2010-08-26 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ結合分子
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
CN101970003A (zh) * 2007-11-09 2011-02-09 诺华有限公司 抗cd40抗体的应用
WO2009062504A1 (en) 2007-11-13 2009-05-22 Tnm Farmguard Aps Secure communication between a client and devices on different private local networks using the same subnet addresses
WO2009074807A2 (en) 2007-12-12 2009-06-18 Imperial Innovations Limited Methods
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
CA2717383C (en) 2008-03-06 2017-01-03 Halozyme, Inc. Large-scale production of soluble hyaluronidase
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
KR101280716B1 (ko) * 2008-03-25 2013-07-01 로슈 글리카트 아게 비-호지킨 림프종의 치료를 위한, 시클로포스파미드, 빈크리스틴 및 독소루비신과 조합으로의 증가된 항체 의존성 세포 세포독성 (ａｄｃｃ) 을 갖는 유형 ⅱ 항-ｃｄ20 항체의 용도
EP2662090A1 (en) 2008-04-14 2013-11-13 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
HRP20151168T1 (hr) 2008-11-07 2015-12-04 Amgen Research (Munich) Gmbh Lijeäśenje akutne limfoblastiäśne leukemije
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
BR112012022223B1 (pt) 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
US20130137134A1 (en) 2010-03-29 2013-05-30 Ben Gurion University Of The Negev Research And Development Authority Method and system for detecting and monitoring hematological cancer
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
DE102010029970B4 (de) 2010-06-11 2021-06-02 Vitesco Technologies GmbH Batterie mit passivem Korrosionsschutz
NZ607473A (en) 2010-09-27 2014-11-28 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CL2013001944A1 (es) 2010-12-30 2014-09-12 Takeda Pharmaceutical Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.
DK2937349T3 (da) 2011-03-23 2017-02-20 Amgen Inc Kondenserede tricykliske dualinhibitorer af cdk 4/6 og flt3
US20140051662A1 (en) 2011-04-08 2014-02-20 Ab Science Treatment of multiple myeloma with masitinib
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
EP2561868A1 (en) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
US20140309183A1 (en) 2011-08-24 2014-10-16 David Kerr Low-Dose Combination Chemotherapy
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
WO2013083140A1 (en) 2011-12-07 2013-06-13 N.V. Nutricia Beta-lactoglobulin peptides for treating cow's milk protein allergy
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
US10093728B2 (en) 2012-03-07 2018-10-09 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
NZ700073A (en) 2012-04-04 2016-08-26 Halozyme Inc Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
ES2658953T3 (es) 2012-09-25 2018-03-13 Morphosys Ag Combinaciones y usos de los mismos
DK2914302T3 (da) 2012-11-05 2017-04-10 Morphosys Ag Radioaktivt markeret antistof samt anvendelser af det
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
CA2893977C (en) 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
WO2014142220A1 (ja) 2013-03-13 2014-09-18 アステラス製薬株式会社 抗腫瘍剤
US20140271644A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
CA2909952C (en) * 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US20140356318A1 (en) 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
US9326320B2 (en) 2013-07-11 2016-04-26 Google Technology Holdings LLC Systems and methods for antenna switches in an electronic device
JP2016534090A (ja) 2013-07-15 2016-11-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ３８アゴニストの医学的使用
EP3063173B1 (en) 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
WO2015067570A2 (en) 2013-11-06 2015-05-14 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
AU2015216875B2 (en) 2014-02-14 2021-02-25 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US10106620B2 (en) 2014-06-16 2018-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
MA41555A (fr) 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3313409A4 (en) 2015-06-29 2018-12-26 Abraxis BioScience, LLC Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
EP3624850A1 (en) 2017-05-18 2020-03-25 Tesaro, Inc. Combination therapies for treating cancer
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
AU2019244478B2 (en) 2018-03-28 2025-11-06 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies
US20190298827A1 (en) 2018-04-03 2019-10-03 Janssen Biotech, Inc. Methods of Treating Multiple Myeloma
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
BR112021007227A2 (pt) 2018-10-17 2021-08-10 Janssen Biotech, Inc. método para fornecer administração subcutânea de anticorpos anti-cd38
AU2019379858B2 (en) 2018-11-13 2024-01-04 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
CN113727729A (zh) 2019-02-22 2021-11-30 詹森生物科技公司 用特异性地结合cd38的抗体、来那度胺和地塞米松的组合治疗新诊断的多发性骨髓瘤的方法
US20200308296A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
WO2020194244A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib and dexamethasone
US20200330593A1 (en) 2019-03-28 2020-10-22 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
WO2020194243A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
WO2020194241A1 (en) 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses
US20200392242A1 (en) 2019-04-19 2020-12-17 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200397896A1 (en) 2019-04-19 2020-12-24 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
US20200405854A1 (en) 2019-04-19 2020-12-31 Janssen Biotech, Inc. Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses
JP7432624B2 (ja) 2019-06-04 2024-02-16 上海科技大学 Ｎａｄ＋及び／又はｎａｄ＋阻害剤及び／又はｎａｄ＋アゴニストの使用及びその配合剤
US20220275101A1 (en) 2021-02-09 2022-09-01 Janssen Biotech, Inc. Use of Approved Anti-CD38 Antibody Drug Product to Treat Light Chain Amyloidosis
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors

Also Published As

Publication number Publication date
EP3110843A1 (en) 2017-01-04
HUE046028T2 (hu) 2020-01-28
CN106459184B (zh) 2021-04-13
EP3110843B1 (en) 2019-09-11
CN106459184A (zh) 2017-02-22
JP2017507953A (ja) 2017-03-23
NZ723535A (en) 2023-09-29
MY180621A (en) 2020-12-03
DOP2016000224A (es) 2017-03-31
GT201600172A (es) 2019-08-15
PL3110843T3 (pl) 2020-02-28
AU2015223205A1 (en) 2016-09-08
CY1122398T1 (el) 2021-01-27
MX378546B (es) 2025-03-06
ES2756349T3 (es) 2020-04-27
US20170174780A1 (en) 2017-06-22
RS59516B1 (sr) 2019-12-31
ME03583B (me) 2020-07-20
ZA201708541B (en) 2018-11-28
ZA201606682B (en) 2022-05-25
AU2015223205B2 (en) 2020-10-29
IL247392A0 (en) 2016-11-30
PT3110843T (pt) 2019-11-19
UA120926C2 (uk) 2020-03-10
CA2940864A1 (en) 2015-09-03
US9603927B2 (en) 2017-03-28
US20210061920A1 (en) 2021-03-04
PH12016501700A1 (en) 2016-10-03
KR20160126026A (ko) 2016-11-01
US20250011457A1 (en) 2025-01-09
MX2016011186A (es) 2017-01-23
CL2016002158A1 (es) 2017-07-28
US12060432B2 (en) 2024-08-13
US20150246123A1 (en) 2015-09-03
BR112016019866A2 (pt) 2017-10-17
SG11201607028XA (en) 2016-09-29
EA201691747A1 (ru) 2017-05-31
SMT201900637T1 (it) 2020-01-14
IL247392B (en) 2020-10-29
PE20161175A1 (es) 2016-11-03
LT3110843T (lt) 2019-11-11
CR20160388A (es) 2016-11-07
SV2016005267A (es) 2017-01-18
SI3110843T1 (sl) 2019-11-29
CA2940864C (en) 2022-07-12
EP3110843A4 (en) 2017-08-09
JP6670248B2 (ja) 2020-03-18
WO2015130728A1 (en) 2015-09-03
US10800851B2 (en) 2020-10-13
HRP20192058T1 (hr) 2020-02-21

Similar Documents

Publication Publication Date Title
IL261395A (en) Combined treatment with antibodies against cd73
SI3110843T1 (sl) Kombinacijske terapije s protitelesi proti-CD38
IL251963A0 (en) Anti-pd-1 antibodies
IL250583A0 (en) Anti-tigit antibodies
IL251033B (en) Combined treatments with anti-cd38 antibodies
IL252422B (en) Effector-deficient anti-cd32a antibodies
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
DK3180087T3 (da) Kombinationsterapier med anti cd40-antistoffer
DK3560954T3 (da) Modificeret j-kæde
IL273265A (en) New combinations for antigen-based therapy
DK3171700T3 (da) Infusionsanlæg
IL250374B (en) Antibodies against ceramide
IL247988A0 (en) Antibodies against hpa–1a
HUE054148T2 (hu) Anti-ORAI1 antitest
EP3160502B1 (en) BI-SPECIFIC ANTIBODIES ANTI-IL4-IL13
LT3628731T (lt) Naujas antipresepsino antikūnas
GB201509493D0 (en) Therapeutic antibody
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies